622 reports of this reaction
2.7% of all RASAGILINE MESYLATE reports
#6 most reported adverse reaction
DIZZINESS is the #6 most commonly reported adverse reaction for RASAGILINE MESYLATE, manufactured by Teva Neuroscience, Inc.. There are 622 FDA adverse event reports linking RASAGILINE MESYLATE to DIZZINESS. This represents approximately 2.7% of all 23,100 adverse event reports for this drug.
Patients taking RASAGILINE MESYLATE who experience dizziness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIZZINESS is a less commonly reported adverse event for RASAGILINE MESYLATE, but still significant enough to appear in the safety profile.
In addition to dizziness, the following adverse reactions have been reported for RASAGILINE MESYLATE:
The following drugs have also been linked to dizziness in FDA adverse event reports:
DIZZINESS has been reported as an adverse event in 622 FDA reports for RASAGILINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIZZINESS accounts for approximately 2.7% of all adverse event reports for RASAGILINE MESYLATE, making it a notable side effect.
If you experience dizziness while taking RASAGILINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.